This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize IMVEXXY™, ANNOVERA™, BIJUVA™ and our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan agreement; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products or preclude the approval of our future drug candidates; the length, cost and uncertain results of future clinical trials; the ability of our licensees to commercialize and distribute our product and product candidates; our reliance on third parties to conduct our manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock and the concentration of power in our stock ownership.

This non-promotional presentation is intended for investor audiences only.
TherapeuticsMD, A Premier Women’s Health Company

**Annovera™**

**vitaMedMD**

**Annovera™**

**Bijuva** (estradiol and progesterone) capsules

**Imvexxy** (estradiol vaginal inserts) 4 mcg - 10 mcg

**CONTRACEPTION**

**PRENATAL CARE**

**CONTRACEPTION/FAMILY PLANNING - PERIMENOPAUSE**

**VASOMOTOR SYMPTOMS**

**DYSPAREUNIA** (Vulvar & Vaginal Atrophy)

**REPRODUCTIVE HEALTH**

**MENOPAUSE MANAGEMENT**

**For Her. For Life.**
IMVEXXY Launch Update

- Total units since launch ~28,200 paid scripts* dispensed to ~12,800 patients
- October total units of ~13,300 paid scripts*
- Refills for October of ~8,100 paid scripts
- New RXs for October of ~5,200 paid scripts
- 58% month over month growth (Sept/Oct)
- Blended starter and maintenance average WAC Q3 ~$230
- Blended starter and maintenance average WAC for October ~$225
- 37% commercial unrestricted coverage**
  - 11% adjudication rate
- 2.2 fills per patient (in the first 4 months)

---

*Units are based on IQVIA and copay redemption data based on utilization of our affordability programs. Cash pay or covered by insurance.

**MMIT
# VVA TRx Launch Comparison

## Imvexxy TRx Launch Comparison

<table>
<thead>
<tr>
<th>Month</th>
<th>Imvexxy</th>
<th>Vagifem 25MG</th>
<th>Osphena</th>
<th>Intrarosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>154</td>
<td>301</td>
<td>42</td>
<td>128</td>
</tr>
<tr>
<td>2</td>
<td>6,276</td>
<td>3,480</td>
<td>661</td>
<td>1,390</td>
</tr>
<tr>
<td>3</td>
<td>8,443</td>
<td>8,849</td>
<td>1,659</td>
<td>2,363</td>
</tr>
<tr>
<td>4</td>
<td>8,443</td>
<td>12,601</td>
<td>2,693</td>
<td>3,945</td>
</tr>
<tr>
<td>5</td>
<td>13,300</td>
<td>21,036</td>
<td>3,476</td>
<td>5,118</td>
</tr>
<tr>
<td>6</td>
<td>23,981</td>
<td>23,981</td>
<td>5,095</td>
<td>6,251</td>
</tr>
<tr>
<td>7</td>
<td>26,719</td>
<td>6,121</td>
<td>6,121</td>
<td>6,875</td>
</tr>
<tr>
<td>8</td>
<td>28,700</td>
<td>7,316</td>
<td>7,316</td>
<td>7,631</td>
</tr>
<tr>
<td>9</td>
<td>36,186</td>
<td>9,203</td>
<td>9,203</td>
<td>9,675</td>
</tr>
<tr>
<td>10</td>
<td>37,160</td>
<td>10,484</td>
<td>10,484</td>
<td>10,633</td>
</tr>
<tr>
<td>11</td>
<td>43,208</td>
<td>13,289</td>
<td>13,289</td>
<td>12,579</td>
</tr>
<tr>
<td>12</td>
<td>45,882</td>
<td>14,487</td>
<td>14,487</td>
<td>13,782</td>
</tr>
<tr>
<td>13</td>
<td>47,882</td>
<td>16,616</td>
<td>16,616</td>
<td>14,669</td>
</tr>
<tr>
<td>14</td>
<td>52,603</td>
<td>18,056</td>
<td>18,056</td>
<td>16,508</td>
</tr>
<tr>
<td>15</td>
<td>48,674</td>
<td>18,998</td>
<td>19,804</td>
<td>16,119</td>
</tr>
<tr>
<td>16</td>
<td>57,675</td>
<td>19,440</td>
<td>20,817</td>
<td>16,765</td>
</tr>
<tr>
<td>17</td>
<td>56,485</td>
<td>20,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>30,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### References:
- Imvexxy is QVIA and copay redemption data.
- Osphena and Intrarosa is SHA PHAST data.
- Vagifem is from IQVIA.
3Q 2018 Financial Update
Commercial Update
VVA TRx Launch Comparison

<table>
<thead>
<tr>
<th>Month</th>
<th>Imvexxy</th>
<th>Osphena</th>
<th>Intrarosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>154</td>
<td>42</td>
<td>128</td>
</tr>
<tr>
<td>2</td>
<td>6,276</td>
<td>661</td>
<td>1,390</td>
</tr>
<tr>
<td>3</td>
<td>8,443</td>
<td>1,659</td>
<td>2,363</td>
</tr>
<tr>
<td>4</td>
<td>13,300</td>
<td>2,693</td>
<td>3,945</td>
</tr>
<tr>
<td>5</td>
<td>6,121</td>
<td>3,476</td>
<td>5,118</td>
</tr>
<tr>
<td>6</td>
<td>7,316</td>
<td>5,095</td>
<td>6,251</td>
</tr>
<tr>
<td>7</td>
<td>9,203</td>
<td>6,121</td>
<td>6,875</td>
</tr>
<tr>
<td>8</td>
<td>10,484</td>
<td>9,203</td>
<td>7,631</td>
</tr>
<tr>
<td>9</td>
<td>13,289</td>
<td>10,484</td>
<td>9,675</td>
</tr>
<tr>
<td>10</td>
<td>14,487</td>
<td>13,289</td>
<td>10,633</td>
</tr>
<tr>
<td>11</td>
<td>16,616</td>
<td>14,487</td>
<td>12,579</td>
</tr>
<tr>
<td>12</td>
<td>15,4</td>
<td>16,616</td>
<td>13,782</td>
</tr>
<tr>
<td>13</td>
<td>14,669</td>
<td></td>
<td>14,669</td>
</tr>
</tbody>
</table>

References:
Imvexxy is QVIA and copay redemption data.
Osphena and Intrarosa is SHA PHAST data.
Vagifem is from IQVIA.
VVA TRx Launch Comparison

TRx Launch Comparison
Vagifem as example of successful launch

<table>
<thead>
<tr>
<th></th>
<th>Month 1</th>
<th>Month 2</th>
<th>Month 3</th>
<th>Month 4</th>
<th>Month 5</th>
<th>Month 6</th>
<th>Month 7</th>
<th>Month 8</th>
<th>Month 9</th>
<th>Month 10</th>
<th>Month 11</th>
<th>Month 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imvexxy</td>
<td>154</td>
<td>6,276</td>
<td>8,443</td>
<td>13,300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>43,208</td>
</tr>
<tr>
<td>Vagifem 25MG</td>
<td>301</td>
<td>3,480</td>
<td>8,849</td>
<td>12,601</td>
<td>17,764</td>
<td>21,036</td>
<td>23,981</td>
<td>26,719</td>
<td>28,700</td>
<td>36,186</td>
<td>37,160</td>
<td>43,208</td>
</tr>
<tr>
<td>Osphena</td>
<td>42</td>
<td>661</td>
<td>1,659</td>
<td>2,693</td>
<td>3,476</td>
<td>5,095</td>
<td>6,121</td>
<td>7,316</td>
<td>9,203</td>
<td>10,484</td>
<td>13,289</td>
<td>14,487</td>
</tr>
<tr>
<td>Intrarosa</td>
<td>128</td>
<td>1,390</td>
<td>2,363</td>
<td>3,945</td>
<td>5,118</td>
<td>6,251</td>
<td>6,875</td>
<td>7,631</td>
<td>9,675</td>
<td>10,633</td>
<td>12,579</td>
<td>13,782</td>
</tr>
</tbody>
</table>

References:
Imvexxy is QVIA and copay redemption data.
Osphena and Intrarosa is SHA PHAST data.
Vagifem is from IQVIA.
Market Growth Through Treatment Compliance

As of October 31, 2018

- 2.2 IMVEXXY fills per patient in the first 4 months*
- Previous two dyspareunia product launches during the first year of launch averaged 1.7 fills per patient**
- IMVEXXY average refill rate ~74%
- Last week of October, over ~2,000 new patients received an IMVEXXY prescription

References:
*Imvexxy fill data is based on IQVIA and copay redemption data.
**Previous two launches is based on Symphony total script data divided by the patient count data from IQVIA total patient tracker info from the 12 months of launch
Next Phase of Growth

- Launched speaker programs across the US
- Adding additional sales reps to increase IMVEXXY market share and launch BIJUVA
- Launching consumer marketing effort Q1 of 2019
- Increasing Bio-Ignite pharmacies with IMVEXXY
- Launch BIJUVA in the 2Q of 2019
- Launch ANNOVERA as early as the 4Q of 2019
Goal to close last remaining large commercial payers contracts in 2018

We are near the end of the expected 6-month payer block

Anticipate strong commercial adjudication will start in Q1 of 2019
<table>
<thead>
<tr>
<th>BIJUVA Substitutable Market</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-Approved</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Off Label Separated Bio-Identical E &amp; P Pills</td>
<td>~3.8 million(^1)</td>
<td>~3 million(^2)</td>
<td>12 – 18 million(^3)</td>
</tr>
<tr>
<td>Combination Synthetic E+P(^1)</td>
<td>$760M-$950M(^4)</td>
<td>$600M-$750M(^4)</td>
<td>$2.4B-$4.5B(^4)</td>
</tr>
<tr>
<td>Compounded Combination Bio-Identical E+P</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2017
2) Includes the following drugs: Activella®, FemHRT®, Angelq®, Generic 17b + Progestins, Prempro®, Premphase®, Duavee®, Brisdelle®
3) Consensus estimate based on Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31, 2017 and Fisher, J. QuintilesIMS, White Paper: A Profile of the US Compounding Pharmacy Market
4) Assume WAC pricing between $200-250

All trademarks are the property of their respective owners.
BIJUVA is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause

**Key Clinical Attributes**

- First and only bio-identical* combination of estradiol to reduce moderate to severe hot flashes combined with progesterone to help reduce the risk to the endometrium
- Strong efficacy and safety data
- Favorable lipid, coagulation and metabolic profiles, compared to the profiles separately established for synthetic progestins and synthetic estrogens
- Low incidence of bleeding and somnolence
- The most common adverse reactions (≥3%) are breast tenderness (10.4%), headache (3.4%), vaginal bleeding (3.4%), vaginal discharge (3.4%), and pelvic pain (3.1%)

**Key Physical Attributes**

- Once-a-day single oral softgel capsule
- One prescription, one copay

*“Bio-identical” refers to estradiol and progesterone that are molecularly identical to the hormones produced naturally in the woman’s body. There is no evidence that bio-identical hormones are safer or more effective than synthetic hormones.
Post-Marketing Commitment

• To further develop and validate in-vitro dissolution to show manufacturing consistency between drug batches of how the drug is released from the capsule in an in-vitro setting for quality control assessments
  • Expect to submit the final report in December to enable Q2 launch

One dose approved by the FDA

• Given the safety and efficacy demonstrated of the higher dose of 1mg estradiol/100 mg progesterone – there was no reason for the lower dose
• Represents the lowest approved dose of bio-identical estradiol in combination with bio-identical progesterone
• Represents over a $1 billion opportunity as the dose HCPs, compounding pharmacists and women prefer

Label statement of a clinically meaningful reduction of 14 hot flashes per week occurring at week 5

• Consistent with the data from other products on the market today
• Same methodology of clinical meaningfulness that established the approval of other products used to treat vasomotor symptoms achieved at Week 4 and sustained through Week 12
BIJUVA Advantages For Stakeholders

**Patients**

- Satisfy demand for bio-identical hormone therapy with a product approved by FDA on safety and efficacy
- Reduce of out-of-pocket costs via insurance coverage
- Convenience of one combination product
- Widely acceptable at pharmacies and not just compounding pharmacies

**Healthcare Providers**

- First and only FDA-approved bio-identical combination hormone therapy
- Clinically validated dose regimen
- Eliminate risks of compounded hormone therapy
- Meet patient demands and reduce patient out-of-pocket costs via insurance coverage
- Follow medical standards of care and society guidelines while reducing liability

**Pharmacies**

- Meet patient and physician demand for bio-identical hormone therapy
- Assuming third-party reimbursement, significantly improve net margin per script
- Lower certain legal and regulatory costs and risks

**FDA/Regulatory Bodies**

- Reduce need for and use of compounded hormone products
- Full enforcement of regulations regarding compounded hormones
Only FDA approved long-acting reversible birth control that doesn’t require a procedure or repeat doctor’s visit

- Empowers women to be in control of their fertility and menstruation
- ANNOVERA is the only user-directed single 12-month birth control product (used in repeated 4-week cycles for 13 cycles)

Highly effective in preventing pregnancy when used as directed (97.3%)

High patient satisfaction in clinical trials\(^1\) (89% overall satisfaction)

Low daily release of ethinyl estradiol (13 mcg)

Only product with new novel progestin - segesterone acetate\(^2\)

- No androgenic, estrogenic or glucocorticoid effects at contraceptive doses

Favorable side effect profile including low rates of discontinuation related to irregular bleeding (1.7%)

Safety profile generally consistent with other CHC products, including boxed warning

---


## ANNOVERA Key Physical Attributes

<table>
<thead>
<tr>
<th>Physical Attributes</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Softer and more pliable than NuvaRing</td>
</tr>
<tr>
<td>▪ Acceptable for women who haven’t had a child (nulliparous) or are not in a monogamous relationship¹</td>
</tr>
<tr>
<td>▪ “Vaginal System” – the only product in a new class of contraception with potential for $0 co-pay</td>
</tr>
<tr>
<td>▪ Cost and convenience (pharmacy and doc visits)</td>
</tr>
<tr>
<td>▪ Does not require refrigeration by HCP</td>
</tr>
</tbody>
</table>

---

¹ Lohr, et al. Use of intrauterine devices in nulliparous women. Contraception 95 (2017); 529-537
TherapeuticsMD, A Premier Women’s Health Company

CONTRACEPTION

PREGNATAL CARE

CONTRACEPTION/FAMILY PLANNING - PERIMENOPAUSE

VASOMOTOR SYMPTOMS

DYSpareunia

(Vulvar & Vaginal Atrophy)

REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT